Agilent Leads Pack at DDT 2003 with Protein Removal System: Do Serum Scientists Benefit? | GenomeWeb

Amid the circus of proteomics product introductions at the Drug Discovery Technology Conference, held this week in Boston, Agilent Technologies unveiled a liquid chromatography polyclonal affinity antibody column that it claims is capable of removing the six most prevalent proteins in human blood serum, with minimal retention of less abundant proteins. (For other products, see table, p. 8.)

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.